156 related articles for article (PubMed ID: 10513325)
1. [The antiparkinson activity of a new adamantane derivative].
Val'dman EA; Voronina TA; Nerobkova LN
Eksp Klin Farmakol; 1999; 62(4):3-6. PubMed ID: 10513325
[TBL] [Abstract][Full Text] [Related]
2. [Effect of the novel aminoadamantane derivative A-7 on Parkinsonian syndrome induced by systemic administration of neurotoxin MPTP].
Nerobkova LN; Val'dman EA; Voronina TA; Markina NV; Sharkova LM
Eksp Klin Farmakol; 2000; 63(3):3-6. PubMed ID: 10934586
[TBL] [Abstract][Full Text] [Related]
3. Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease.
Luthra PM; Barodia SK; Raghubir R
J Neurosci Methods; 2009 Apr; 178(2):284-90. PubMed ID: 19146880
[TBL] [Abstract][Full Text] [Related]
4. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
[TBL] [Abstract][Full Text] [Related]
5. In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
Sarre S; Lanza M; Makovec F; Artusi R; Caselli G; Michotte Y
Eur J Pharmacol; 2008 Apr; 584(2-3):297-305. PubMed ID: 18342306
[TBL] [Abstract][Full Text] [Related]
6. The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA.
Alam M; Mayerhofer A; Schmidt WJ
Behav Brain Res; 2004 May; 151(1-2):117-24. PubMed ID: 15084427
[TBL] [Abstract][Full Text] [Related]
7. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
Dekundy A; Pietraszek M; Schaefer D; Cenci MA; Danysz W
Brain Res Bull; 2006 Apr; 69(3):318-26. PubMed ID: 16564428
[TBL] [Abstract][Full Text] [Related]
8. MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats.
Ossowska K; Konieczny J; Wolfarth S; Pilc A
Neuropharmacology; 2005 Sep; 49(4):447-55. PubMed ID: 15919101
[TBL] [Abstract][Full Text] [Related]
9. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
[TBL] [Abstract][Full Text] [Related]
11. [Comparative study of neurophysiological effects of adamantane derivatives in the experimental parkinsonism model].
Katunina EA; Samoĭlova EV; Val'dman EA; Nerobkova LN; Voronina TA; Avakian GN
Eksp Klin Farmakol; 2004; 67(2):16-8. PubMed ID: 15188753
[TBL] [Abstract][Full Text] [Related]
12. FK506 as effective adjunct to L-dopa in reserpine-induced catalepsy in rats.
Singh A; Naidu PS; Kulkarni SK
Indian J Exp Biol; 2003 Nov; 41(11):1264-8. PubMed ID: 15332494
[TBL] [Abstract][Full Text] [Related]
13. [Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome].
Kapitsa IG; Ivanova EA; Nepoklonov AV; Kokshenev II; Voronina TA; Val'dman EA
Eksp Klin Farmakol; 2011; 74(7):9-12. PubMed ID: 21894760
[TBL] [Abstract][Full Text] [Related]
14. Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
Samadi P; Grégoire L; Hadj Tahar A; Di Paolo T; Rouillard C; Bédard PJ
Neuropharmacology; 2005 Aug; 49(2):165-73. PubMed ID: 15996565
[TBL] [Abstract][Full Text] [Related]
15. Anti-Parkinsonian Activity of Hemantane on a Model of Hemiparkinsonian Syndrome in Rats.
Ivanova EA; Kapitsa IG; Val'dman EA; Voronina TA
Bull Exp Biol Med; 2015 Jul; 159(3):380-3. PubMed ID: 26212814
[TBL] [Abstract][Full Text] [Related]
16. On the interaction between neuroleptics and antiparkinson drugs.
Julou L
Mod Probl Pharmacopsychiatry; 1970; 5():50-4. PubMed ID: 5527168
[No Abstract] [Full Text] [Related]
17. Pleiotrophin receptor RPTP-zeta/beta expression is up-regulated by L-DOPA in striatal medium spiny neurons of parkinsonian rats.
Ferrario JE; Rojas-Mayorquín AE; Saldaña-Ortega M; Salum C; Gomes MZ; Hunot S; Raisman-Vozari R
J Neurochem; 2008 Oct; 107(2):443-52. PubMed ID: 18752647
[TBL] [Abstract][Full Text] [Related]
18. [The antiparkinson activity of muscarinic antagonists depending on their selectivity for individual m-cholinoreceptor subtypes].
Kosmachev AB; Beliaev VA; Khrabrova AV; Fil'ko OA; Libman NM
Eksp Klin Farmakol; 1998; 61(5):3-5. PubMed ID: 9854621
[TBL] [Abstract][Full Text] [Related]
19. Chronic high-frequency stimulation of the subthalamic nucleus and L-DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission.
Gubellini P; Eusebio A; Oueslati A; Melon C; Kerkerian-Le Goff L; Salin P
Eur J Neurosci; 2006 Sep; 24(6):1802-14. PubMed ID: 17004943
[TBL] [Abstract][Full Text] [Related]
20. On the coexistence of parkinsonism and tardive dyskinesia.
Fann WE; Lake CR
Dis Nerv Syst; 1974 Jul; 35(7):324-6. PubMed ID: 17894090
[No Abstract] [Full Text] [Related]
[Next] [New Search]
